Day: June 28, 2014

AstraZeneca has suffered a setback with advisors to the US Food and Drug Administration recommending against accelerated approval of olaparib for ovarian cancer. The agency’s Oncologic Drugs Advisory Committee has voted 11 to 2 that current evidence does not support … Continue reading →

Advisors to the European Medicines Agency have backed Roche’s blockbuster Avastin for the most difficult to treat form of ovarian cancer. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve the use … Continue reading →